New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:16 EDTAERI, AGNAerie Pharmaceuticals won't be hurt by Allergan move, says RBC Capital
After Allergan (AGN) said it plans to initiate a Phase III trial for its long-acting prostaglandin glaucoma treatment, RBC Capital does not expect Allergan's move to hurt Aerie (AERI), as Aerie's Roclatan has demonstrated statistically significant superiority to a prostaglandin, according to the firm. Moreover, RBC believes that the glaucoma market is large enough to enable multiple products to succeed. It recommends buying Aerie's stock at current levels.
News For AERI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
17:22 EDTAGNAllergan to acquire AqueSys for $300M upfront payment
Subscribe for More Information
17:18 EDTAGNAllergan to acquire AqueSys for $300M upfront payment
September 2, 2015
07:17 EDTAGNAllergan announces FDA approval of updated label for TEFLARO
Subscribe for More Information
07:09 EDTAGNAllergan announces topline results from RECAPTURE 1 and 2
Allergan announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ as a treatment for adult hospitalized patients with complicated urinary tract infections, including pyelonephritis. AVYCAZ consists of a cephalosporin, ceftazidime, an established treatment for serious bacterial infections, and the first and only non-beta lactam beta-lactamase inhibitor, avibactam. The addition of avibactam protects ceftazidime from being broken down by certain beta-lactamases that are produced by these resistant bacteria. The global RECAPTURE 1 and 2 Phase III studies evaluated the safety and efficacy of AVYCAZ administered intravenously as a two-hour infusion, compared to doripenem, administered intravenously as a 30-minute infusion, in hospitalized adult patients with cUTI, including pyelonephritis. Data from the studies were analysed as a single-pooled dataset with the agreement of the US FDA and the EMA. AVYCAZ was also effective in treating cUTI patients infected with ceftazidime-resistant bacteria. Allergan plans to submit this data as a supplemental New Drug Application (sNDA) to the Food and Drug Administration by the end of 2015.
August 31, 2015
08:04 EDTAGNAllergan completes Nuarex acquisition
Subscribe for More Information
07:39 EDTAGNCiti calls Allergan a 'stock to own,' keeps $360 target
Citi analyst Liav Abraham calls Allergan a "stock to own" given its "attractive" organic growth profile, pipeline potential and ability to do more acquisitions. He reiterates a Buy rating on the stock with a $360 price target.
August 28, 2015
09:50 EDTAGNAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
August 25, 2015
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
August 24, 2015
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use